Patents by Inventor Curtis Wright

Curtis Wright has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7943173
    Abstract: Disclosed in certain embodiments is a pharmaceutical composition comprising from 10 to 40 mg of oxycodone or a pharmaceutically acceptable salt thereof and 0.65 to 0.90 mg naloxone or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 18, 2002
    Date of Patent: May 17, 2011
    Assignee: Purdue Pharma L.P.
    Inventors: Christopher D. Breder, Robert D. Colucci, Stephen A Howard, Benjamin Oshlack, Curtis Wright
  • Publication number: 20110104214
    Abstract: The invention is directed to sustained release formulations containing oxycodone or a pharmaceutically acceptable salt thereof which provide a mean C24/Cmax oxycodone ratio of 0.6 to 1.0 or 0.7 to 1 after oral administration at steady state to patients and methods thereof.
    Type: Application
    Filed: November 1, 2010
    Publication date: May 5, 2011
    Applicant: Purdue Pharma L.P.
    Inventors: Benjamin Oshlack, Curtis Wright, Derek Prater
  • Publication number: 20110097404
    Abstract: Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is not released when the dosage form is administered orally intact.
    Type: Application
    Filed: October 21, 2010
    Publication date: April 28, 2011
    Applicant: Purdue Pharma L.P.
    Inventors: Benjamin Oshlack, Curtis Wright, J. David Haddox
  • Patent number: 7914818
    Abstract: Disclosed are oral dosage forms, comprising (i) a therapeutically effective amount of an opioid agonist; (ii) an opioid antagonist in releasable form; and (iii) a sequestered opioid antagonist which is not released when the dosage form is administered intact, and methods thereof.
    Type: Grant
    Filed: August 6, 2002
    Date of Patent: March 29, 2011
    Assignee: Purdue Pharma L.P.
    Inventors: Christopher Breder, Curtis Wright, Benjamin Oshlack
  • Publication number: 20110020450
    Abstract: The present invention relates to a titratable dosage transdermal delivery system for systemic delivery of a therapeutic agent or drug. The system comprises a plurality of patch units that are connected along one or more borders. The plurality of patch units are divisible into units along the one or more borders having one or more lines of separation. Each patch unit is surrounded by a border. The therapeutic patch has at least a backing layer and a therapeutic agent comprising layer. The dosage of therapeutic agent delivered to a patient is proportional to the number of patch unit applied per treatment. The system enables systemic administration of a titratable dosage of therapeutic agent, adjustable by the patient under the direction of a physician, through the skin or mucosa. Moreover, the invention relates to a method of making the titratable dosage transdermal delivery system.
    Type: Application
    Filed: September 30, 2010
    Publication date: January 27, 2011
    Inventor: Curtis Wright, IV
  • Patent number: 7846476
    Abstract: The invention is directed to sustained release formulations containing oxycodone or a pharmaceutically acceptable salt thereof which provide a mean C24/Cmax oxycodone ratio of 0.6 to 1.0 or 0.7 to 1 after oral administration at steady state to patients and methods thereof.
    Type: Grant
    Filed: May 2, 2002
    Date of Patent: December 7, 2010
    Assignee: Purdue Pharma L.P.
    Inventors: Benjamin Oshlack, Curtis Wright, Derek Prater
  • Patent number: 7842309
    Abstract: Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact.
    Type: Grant
    Filed: November 4, 2003
    Date of Patent: November 30, 2010
    Assignee: Purdue Pharma L.P.
    Inventors: Benjamin Oshlack, Curtis Wright, J. David Haddox
  • Patent number: 7842311
    Abstract: Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact.
    Type: Grant
    Filed: October 21, 2003
    Date of Patent: November 30, 2010
    Assignee: Purdue Pharma L.P.
    Inventors: Benjamin Oshlack, Curtis Wright, J. David Haddox
  • Patent number: 7842307
    Abstract: Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of an opioid analgesic, an opioid antagonist and one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid.
    Type: Grant
    Filed: August 6, 2002
    Date of Patent: November 30, 2010
    Assignee: Purdue Pharma L.P.
    Inventors: Benjamin Oshlack, Curtis Wright, Christopher Breder
  • Patent number: 7790215
    Abstract: Disclosed in certain embodiments is a coating comprising a pharmaceutically acceptable mixture of gelatin and hydrophobic polymer.
    Type: Grant
    Filed: March 26, 2003
    Date of Patent: September 7, 2010
    Assignee: Purdue Pharma LP
    Inventors: Richard S. Sackler, Benjamin Oshlack, Curtis Wright
  • Publication number: 20100168148
    Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
    Type: Application
    Filed: December 8, 2009
    Publication date: July 1, 2010
    Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
  • Patent number: 7718192
    Abstract: Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact.
    Type: Grant
    Filed: November 4, 2003
    Date of Patent: May 18, 2010
    Assignee: Purdue Pharma L.P.
    Inventors: Benjamin Oshlack, Curtis Wright, J. David Haddox
  • Patent number: 7682632
    Abstract: Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact.
    Type: Grant
    Filed: November 4, 2003
    Date of Patent: March 23, 2010
    Assignee: Purdue Pharma L.P.
    Inventors: Benjamin Oshlack, Curtis Wright, J. David Haddox
  • Patent number: 7658939
    Abstract: Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact.
    Type: Grant
    Filed: November 4, 2003
    Date of Patent: February 9, 2010
    Assignee: Purdue Pharma L.P.
    Inventors: Benjamin Oshlack, Curtis Wright, J. David Haddox
  • Publication number: 20090081287
    Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
    Type: Application
    Filed: October 30, 2008
    Publication date: March 26, 2009
    Applicant: Purdue Pharma L.P.
    Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
  • Publication number: 20080319085
    Abstract: A titration dosing regimen for the administration of controlled release tramadol analgesic to patients. The titration dosing regimen provides a significant reduction in the occurrence of adverse effects from the introduction of controlled released tramadol dosing, thus increasing patient compliance and medication tolerability.
    Type: Application
    Filed: August 18, 2008
    Publication date: December 25, 2008
    Inventors: Curtis Wright, Robert Colucci, Raymond Sanchez
  • Publication number: 20080311199
    Abstract: Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact, such that the ratio of the amount of antagonist released from said dosage form after tampering to the amount of said antagonist released from said intact dosage form is about 4:1 or greater, based on the in-vitro dissolution at 1 hour of said dosage form in 900 ml of Simulated Gastric Fluid using a USP Type II (paddle) apparatus at 75 rpm at 37 degrees C. wherein said agonist and antagonist are interdispersed and are not isolated from each other in two distinct layers.
    Type: Application
    Filed: November 4, 2003
    Publication date: December 18, 2008
    Applicant: PURDUE PHARMA L.P.
    Inventors: Benjamin Oshlack, Curtis Wright, J. David Haddox
  • Publication number: 20080311198
    Abstract: Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact, such that the ratio of the amount of antagonist released from said dosage form after tampering to the amount of said antagonist released from said intact dosage form is about 4:1 or greater, based on the in-vitro dissolution at 1 hour of said dosage form in 900 ml of Simulated Gastric Fluid using a USP Type II (paddle) apparatus at 75 rpm at 37 degrees C. wherein said agonist and antagonist are interdispersed and are not isolated from each other in two distinct layers.
    Type: Application
    Filed: November 4, 2003
    Publication date: December 18, 2008
    Applicant: PURDUE PHARMA L.P.
    Inventors: Benjamin Oshlack, Curtis Wright, J. David Haddox
  • Publication number: 20080306104
    Abstract: Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact, such that the ratio of the amount of antagonist released from said dosage form after tampering to the amount of said antagonist released from said intact dosage form is about 4:1 or greater, based on the in-vitro dissolution at 1 hour of said dosage form in 900 ml of Simulated Gastric Fluid using a USP Type II (paddle) apparatus at 75 rpm at 37 degrees C. wherein said agonist and antagonist are interdispersed and are not isolated from each other in two distinct layers.
    Type: Application
    Filed: November 4, 2003
    Publication date: December 11, 2008
    Applicant: PURDUE PHARMA L.P.
    Inventors: Benjamin Oshlack, Curtis Wright, J. David Haddox
  • Publication number: 20080305167
    Abstract: Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact, such that the ratio of the amount of antagonist released from said dosage form after tampering to the amount of said antagonist released from said intact dosage form is about 4:1 or greater, based on the in-vitro dissolution at 1 hour of said dosage form in 900 ml of Simulated Gastric Fluid using a USP Type II (paddle) apparatus at 75 rpm at 37 degrees C. wherein said agonist and antagonist are interdispersed and are not isolated from each other in two distinct layers.
    Type: Application
    Filed: November 4, 2003
    Publication date: December 11, 2008
    Applicant: PURDUE PHARMA L.P.
    Inventors: Benjamin Oshlack, Curtis Wright, J. David Haddox